These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7652093)

  • 21. [Risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol].
    López Ibor JJ; Ayuso JL; Gutiérrez M; Guimon J; Herraiz ML; Chinchilla A; Ayuso JL; González Pinto A; Eguiluz I; Fernández A
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1996; 24(4):165-72. PubMed ID: 8984849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The response of untreated chronic schizophrenics to haloperidol and haloperidol decanoate.
    Leff JP; Tress KH
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():27-40. PubMed ID: 3559160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate.
    Kane JM
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):20S-23S. PubMed ID: 2870088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Side effects during long-term treatment with depot antipsychotic medication.
    Cookson JC
    Clin Neuropharmacol; 1991; 14 Suppl 2():S24-30; discussion S30-2. PubMed ID: 1751940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Depressive symptoms and schizophrenia a psychopharmacological approach.
    Mauri MC; Bravin S; Fabiano L; Vanni S; Boscati L; Invernizzi G
    Encephale; 1995; 21(5):555-8. PubMed ID: 8529564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
    J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
    Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation of effectiveness and tolerance of the long-term treatment with bromoperidol decanoate in psychotic disorders].
    Levi Minzi A; Laviani M
    Minerva Psichiatr; 1992; 33(1):51-5. PubMed ID: 1406161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment with bromperidol in schizophrenic patients].
    Ellerman LA
    Acta Psiquiatr Psicol Am Lat; 1989; 35(1-2):23-30. PubMed ID: 2634329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trial with bromperidol in psychotic states.
    Brasseur R
    Acta Psychiatr Belg; 1978; 78(1):110-7. PubMed ID: 645404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia.
    Kane JM; Davis JM; Schooler N; Marder S; Casey D; Brauzer B; Mintz J; Conley R
    Am J Psychiatry; 2002 Apr; 159(4):554-60. PubMed ID: 11925292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term depot neuroleptic treatment with perphenazine decanoate. II. Different depot intervals in the last 6 months of a 12 month study of 42 drug monitored psychotic patients.
    Knudsen P; Hansen LB; Højholdt K; Larsen NE
    Acta Psychiatr Scand Suppl; 1985; 322():41-50. PubMed ID: 3934921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Haloperidol decanoate: results of a 6-month open trial in paranoid schizophrenia].
    Pérez C; Stier Rosner SE
    Acta Psiquiatr Psicol Am Lat; 1989; 35(3-4):111-5. PubMed ID: 2576990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacology, pharmacokinetics and clinical development of haloperidol decanoate.
    Gelders YG
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():1-11. PubMed ID: 3559159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evaluation of the efficacy of haloperidol decanoate in the treatment of chronic psychotic hospital patients].
    Marchant N; Caruso S; Cuervo L; Brizuela A
    Acta Psiquiatr Psicol Am Lat; 1985 Mar; 31(1):37-41. PubMed ID: 2864788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Neuroleptic large dose therapy of schizophrenias].
    Ungvári G; Pethö B
    Psychiatr Neurol Med Psychol (Leipz); 1981 Apr; 33(4):230-6. PubMed ID: 6114506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Haloperidol decanoate. Results of an open-ended multicentric study in chronic psychotic states].
    Lemperiere T; Ropert R; Leger JM; Alexandre JY; Clerc G; Darondel A; Delaunay J; Delteil P; Malauzat D; Raynaud J
    Encephale; 1984; 10(5):217-22. PubMed ID: 6519017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low- and standard-dose depot haloperidol combined with targeted oral neuroleptics.
    Huttunen MO; Tuhkanen H; Haavisto E; Nyholm R; Pitkänen M; Raitasuo V; Romanov M
    Psychiatr Serv; 1996 Jan; 47(1):83-5. PubMed ID: 8925352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A loading-dose strategy for converting from oral to depot haloperidol.
    Ereshefsky L; Toney G; Saklad SR; Anderson C; Seidel D
    Hosp Community Psychiatry; 1993 Dec; 44(12):1155-61. PubMed ID: 7907570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.